Abstract
The transmembrane metzinkin-proteases of the ADAM (a disintegrin and a metalloproteinase)-family ADAM10 and ADAM 17 are both implicated in the ectodomain shedding of various cell surface molecules including the IL6-receptor and the transmembrane chemokines CX3CL1 and CXCL16. These molecules are constitutively released from cultured cells, a process that can be rapidly enhanced by cell stimulation with phorbol esters such as PMA. Recent research supports the view that the constitutive cleavage predominantly involves ADAM10 while the inducible one is mediated to a large extent by ADAM17. We here describe the discovery of hydroxamate compounds with different potency against ADAM10 and ADAM17 and different ability to block constitutive and inducible cleavage of IL6R, CX3CL1 and CXCL16 by the two proteases. By screening a number of hydroxamate inhibitors for the inhibition of recombinant metalloproteinases, a compound was found inhibiting ADAM10 with more than 100-fold higher potency than ADAM17, which may be explained by an improved fit of the compound to the S1 specificity pocket of ADAM10 as compared to that of ADAM17. In cell-based cleavage experiments this compound (GI254023X) potently blocked the constitutive release of IL6R, CX3CL1 and CXCL16, which was in line with the reported involvement of ADAM10 but not ADAM17 in this process. By contrast, the compound did not affect the PMA-induced shedding, which was only blocked by GW280264X, a potent inhibitor of ADAM17. As expected, GI254023X did not further decrease the residual release of CX3CL1 and CXCL16 in ADAM10-deficient cells verifying that the
Keywords: metalloproteinase, adam10, adam17, hydroxamate inhibitors, shedding, interleukin 6, transmembrane chemokines
Combinatorial Chemistry & High Throughput Screening
Title: Metalloproteinase Inhibitors for the Disintegrin-Like Metalloproteinases ADAM10 and ADAM17 that Differentially Block Constitutive and Phorbol Ester-Inducible Shedding of Cell Surface Molecules
Volume: 8 Issue: 2
Author(s): Andreas Ludwig, Christian Hundhausen, Millard H. Lambert, Neil Broadway, Robert C. Andrews, D. Mark Bickett, M. Anthony Leesnitzer and J. David Becherer
Affiliation:
Keywords: metalloproteinase, adam10, adam17, hydroxamate inhibitors, shedding, interleukin 6, transmembrane chemokines
Abstract: The transmembrane metzinkin-proteases of the ADAM (a disintegrin and a metalloproteinase)-family ADAM10 and ADAM 17 are both implicated in the ectodomain shedding of various cell surface molecules including the IL6-receptor and the transmembrane chemokines CX3CL1 and CXCL16. These molecules are constitutively released from cultured cells, a process that can be rapidly enhanced by cell stimulation with phorbol esters such as PMA. Recent research supports the view that the constitutive cleavage predominantly involves ADAM10 while the inducible one is mediated to a large extent by ADAM17. We here describe the discovery of hydroxamate compounds with different potency against ADAM10 and ADAM17 and different ability to block constitutive and inducible cleavage of IL6R, CX3CL1 and CXCL16 by the two proteases. By screening a number of hydroxamate inhibitors for the inhibition of recombinant metalloproteinases, a compound was found inhibiting ADAM10 with more than 100-fold higher potency than ADAM17, which may be explained by an improved fit of the compound to the S1 specificity pocket of ADAM10 as compared to that of ADAM17. In cell-based cleavage experiments this compound (GI254023X) potently blocked the constitutive release of IL6R, CX3CL1 and CXCL16, which was in line with the reported involvement of ADAM10 but not ADAM17 in this process. By contrast, the compound did not affect the PMA-induced shedding, which was only blocked by GW280264X, a potent inhibitor of ADAM17. As expected, GI254023X did not further decrease the residual release of CX3CL1 and CXCL16 in ADAM10-deficient cells verifying that the
Export Options
About this article
Cite this article as:
Ludwig Andreas, Hundhausen Christian, Lambert H. Millard, Broadway Neil, Andrews C. Robert, Bickett Mark D., Leesnitzer Anthony M. and Becherer David J., Metalloproteinase Inhibitors for the Disintegrin-Like Metalloproteinases ADAM10 and ADAM17 that Differentially Block Constitutive and Phorbol Ester-Inducible Shedding of Cell Surface Molecules, Combinatorial Chemistry & High Throughput Screening 2005; 8(2) . https://dx.doi.org/10.2174/1386207053258488
DOI https://dx.doi.org/10.2174/1386207053258488 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cyclophilins in Atherosclerosis: A New Therapeutic Target?
Current Pharmaceutical Design Patterns of Expression of Viral and Cytokine Gene Transcripts During Mouse Polyoma Virus Infection
Combinatorial Chemistry & High Throughput Screening Cytokines in Candidiasis and Aspergillosis
Current Pharmaceutical Biotechnology Mapracorat, a Novel Non-Steroidal Selective Glucocorticoid Receptor Agonist for the Treatment of Allergic Conjunctivitis
Inflammation & Allergy - Drug Targets (Discontinued) Pulmonary Drug Delivery: A Role for Polymeric Nanoparticles?
Current Topics in Medicinal Chemistry Visceral Adipose Tissue and Atherosclerosis
Current Vascular Pharmacology Acne Vulgaris: an Inflammatory Disease Even Before the Onset of Clinical Lesions
Inflammation & Allergy - Drug Targets (Discontinued) Phytosterols in Physiological Concentrations Target Multidrug Resistant Cancer Cells
Medicinal Chemistry Toll-Like Receptor Signaling Mechanisms Involved in Dendritic Cell Activation: Potential Therapeutic Control of T Cell Polarization
Current Pharmaceutical Design Recommendations for the Treatment of Hypertension in Elderly People
Cardiovascular & Hematological Agents in Medicinal Chemistry Design and Structure of Peptide and Peptidomimetic Antagonists of Protein- Protein Interaction
Current Protein & Peptide Science Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry Nanotechnology-based Drug Delivery Systems as Potential for Skin Application: A Review
Current Medicinal Chemistry Obesity Associated Modulation of miRNA and Co-Regulated Target Transcripts in Human Adipose Tissue of Non-Diabetic Subjects
MicroRNA Controlled-release Particulate Cytokine Adjuvants for Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia
Current Cancer Drug Targets Biology of Protooncogene c-kit Receptor and Spermatogenesis
Current Pharmacogenomics The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Influence of Adrenalectomy on Protective Effects of Urocortin I, a Corticotropin-Releasing Factor, Against Indomethacin-Induced Enteropathy in Rats
Current Neuropharmacology